HK Stock Market Move | EAST BUY (01797) rose over 23% at one point during the trading day, but dropped over 9% towards the end of the day. The turnover rate for the whole day has exceeded 10%.
Eastern Selection (01797) surged to a high of 24% at the end of the session, but quickly fell afterwards. As of the time of writing, it has dropped 8.94%, closing at 39.5 Hong Kong dollars with a turnover of 49.88 billion Hong Kong dollars. The turnover rate for the whole day has exceeded 10%.
EAST BUY (01797) surged by as much as 24% during the final trading session, but quickly dropped and fell by 8.94% to 39.5 Hong Kong dollars at the time of writing, with a total trading volume of 49.88 billion Hong Kong dollars and a turnover rate exceeding 10% for the day.
On the news front, EAST BUY is set to release its full-year results for the fiscal year ending May 31, 2025 on August 22 (Friday). Previously, New Oriental announced its fourth quarter results for the 25th fiscal year, with revenue of 1.5 billion US dollars, a decrease of about 30% year-on-year but a narrowing decline compared to the previous quarter; Non-GAAP operating profit is around 790 million RMB, corresponding to an operating profit margin of about 7%, an increase compared to the previous quarter. The bank stated that the company's profitability has continued to improve after the controversy of splitting from Hu Tongxing and the departure of head anchor Dn Dn. The bank recommended focusing on the company's transition from being driven by anchors to being driven by products.
Related Articles

ZCLOUD TECH CON (09900) issued 2.604 billion shares due to stock split.

JIANGSU EXPRESS (00177) has completed the issuance of 500 million yuan in short-term financing notes.

REMEGEN (09995): The National Medical Products Administration Drug Evaluation Center has awarded breakthrough therapy designation to RC148 for the treatment of non-small cell lung cancer.
ZCLOUD TECH CON (09900) issued 2.604 billion shares due to stock split.

JIANGSU EXPRESS (00177) has completed the issuance of 500 million yuan in short-term financing notes.

REMEGEN (09995): The National Medical Products Administration Drug Evaluation Center has awarded breakthrough therapy designation to RC148 for the treatment of non-small cell lung cancer.

RECOMMEND

Former Innovative Pharma Star Faces Growing Pains—Why Zai Lab’s Stock Tumbled Despite Strong Results
18/08/2025

World Humanoid Robot Games In-Depth: Competition Drives Technological Innovation and Accelerates Industry Progress
18/08/2025

Guangdong Cross-Border E-Commerce: Tariff Pressures Spur Overseas Warehouse Boom as Sellers Target Russia and Latin America
18/08/2025